OPT - Opthea to Present at the Jefferies 2023 London Healthcare Conference | Benzinga
MELBOURNE, Australia, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, ASX:OPT)), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company's Founder and Chief Innovation Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference being held on November 14th -16th, 2023.
Dr. Baldwin's fireside chat with Jefferies Analyst, Kelly Shi, will occur on Wednesday, November 15th at 12:20PM – 12:55 PM GMT (11:20 PM November 15th AEDT), which can be accessed live by registering at: https://wsw.com/webcast/jeff287/opt/1727508. An archive of the presentation may be accessed for 90 days on the Investors page of the Opthea website at https://ir.opthea.com/events-presentations.
About Opthea Limited
Opthea ((ASX:OPT, NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea's lead product candidate OPT-302 is in pivotal Phase 3 clinical trials and being developed for use in combination with anti-VEGF-A monotherapies to achieve broader inhibition of the VEGF family, with the goal of improving overall efficacy and demonstrating superior vision gains over that which can be ...